A Multicenter, Open-Label, Phase 1 Trial of SHR3162 Given Orally to Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Fluzoparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Atridia; Jiangsu Hengrui Medicine Co.
- 23 Apr 2017 Planned End Date changed from 1 Nov 2020 to 1 Dec 2018.
- 23 Apr 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2018.
- 14 Sep 2016 Status changed from not yet recruiting to recruiting.